News Search Results
May 12, 2026, 03:00 ET SkylineDx to Showcase New Cutaneous Squamous Cell Carcinoma Findings at 83rd Society for Investigative Dermatology Annual Meeting
and nomograms based on clinicopathological factors, to ultimately improve patient outcomes."About SkylineDxSkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology, and inflammatory and infectious diseases. SkylineDx uses its expertise
More news about: SkylineDx
May 11, 2026, 16:01 ET HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
May 11, 2026, 13:33 ET DNA Synthesis Market to Reach $30.4 billion, Globally, by 2035 at 18.2% CAGR: Allied Market Research
The DNA synthesis market is witnessing strong adoption across pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations (CROs), and synthetic biology firms due to its critical role in enabling advanced genetic research and biopharmaceutical development.
More news about: Allied Market Research
May 11, 2026, 12:50 ET IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
844-916-0895ImmunityBio, Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: Hagens Berman Sobol Shapiro LLP
May 11, 2026, 12:44 ET Honoring Dr. J. Craig Venter's Legacy, Human Longevity Launches Clinical-Grade $599 Whole Genome Sequencing Report with AI-Enhanced Insights for Proactive Disease Prevention
Human Longevity WebsiteAbout Human Longevity, Inc.Founded in 2013, Human Longevity, Inc. is a biotechnology company at the forefront of integrating genomics, artificial intelligence, and multimodal diagnostics to extend human healthspan founded by genomics
More news about: Human Longevity, Inc.
May 11, 2026, 12:41 ET DNA Polymerase Market to Reach USD 725.8 Million by 2035 as Molecular Diagnostics and High-Fidelity Enzymes Accelerate Precision Genomics
sequencing (NGS), expansion of personalized medicine, and increasing demand for high-fidelity DNA amplification technologies across healthcare and biotechnology sectors.
More news about: Future Market Insights
May 11, 2026, 11:48 ET /C O R R E C T I O N -- Anixa Biosciences, Inc./
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations from its ongoing Phase 1 clinical
More news about: Anixa Biosciences, Inc.
May 11, 2026, 09:00 ET Ranok Therapeutics Announces the Publication of Positive Phase 1a Clinical Results for KRAS G12D Inhibitor RNK08954 in Cancer Discovery
BOSTON and HANGZHOU, China, May 11, 2026 /PRNewswire/ -- Ranok Therapeutics, a clinical-stage biotechnology company developing innovative therapies, today announced the publication of preliminary clinical results from its Phase 1a study of RNK08954 in
More news about: Ranok Therapeutics
May 11, 2026, 08:36 ET DYPIU Signs MoU with Dassault Systèmes to Establish Experience Centre
forward a strong tradition of academic innovation and nation-building. The university offers programmes across engineering, management, design, biotechnology, media, liberal arts, and emerging technologies, with a strong emphasis on industry collaboration, global exposure, entrepreneurship, and skill
More news about: D Y Patil International University
May 11, 2026, 08:31 ET MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
CAMBRIDGE, Mass., May 11, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a late-breaking abstract highlighting DA-1726, a novel dual oxyntomodulin
More news about: MetaVia Inc.
May 11, 2026, 08:00 ET HydroGene to present non-viral DNA delivery in non-human primates demonstrating expression and durability comparable to commercial AAV products at ASGCT 2026
HydroGene Therapeutics is a biotechnology company creating accessible gene therapies for all liver diseases. HydroGene is proud to announce our upcoming presentations at the 2026
More news about: HydroGene Therapeutics
May 11, 2026, 08:00 ET Vasa Therapeutics Announces Oral Presentation on VS-214 at the 2026 Vascular Discovery Meeting of American Heart Association
ENCINITAS, Calif., May 11, 2026 /PRNewswire/ -- Vasa Therapeutics ("Vasa"), a clinical stage biotechnology company developing novel therapies for cardiovascular and metabolic aging, announced today that its abstract titled, "Discovery of VS-214, a
More news about: Vasa Therapeutics
May 11, 2026, 08:00 ET Ruder Finn Appoints Kelley Yoder, Global Head of Health and Life Sciences, Signaling Major Investment in Next Phase of Growth
Global Head of Health and Life Sciences, strengthening the firm's leadership team and accelerating the continued growth across pharmaceutical, biotechnology, medical device, and diagnostic industries. Yoder will enhance Ruder Finn's ability to deliver integrated healthcare solutions at the intersection
More news about: Ruder Finn
May 11, 2026, 06:00 ET Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner's National Priority Voucher
LEXINGTON, Mass., May 11, 2026 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved BIZENGRI® (zenocutuzumab-zbco) for the treatment
More news about: Partner Therapeutics, Inc.
May 11, 2026, 05:03 ET Sino Biological Unveils EliteScience VIP Partnership Program for European Researchers
service, we help partners turn ideas into impact faster."About Sino BiologicalFounded in 2007, Sino Biological is a global biotechnology company specializing in high-quality recombinant proteins, antibodies, and CRO services. Serving researchers in over 90 countries, Sino Biological
More news about: Sino Biological
May 11, 2026, 02:05 ET Pramurta Sinha from CGC Landran secures Rs. 1.14 Crore package
15,000 students from across India and offers 55+ undergraduate and postgraduate programmes in Engineering, Business Management & Commerce, Biotechnology, Pharmacy and Hotel Management. The institution has secured NAAC A+ ranking and is also recognized by NBA, NIRF, QS I-Gauge and IIC. Supported by
More news about: CGC Landran
May 09, 2026, 13:30 ET ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D
innovative drug development worldwide.About ACROBiosystems GroupACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models.
More news about: ACROBiosystems Group
May 09, 2026, 10:34 ET ACROBiosystems Launches Global License Solution Upgrade for HEK293 Functional Cell Lines, Streamlining Compliance to Accelerate Biopharmaceutical R&D
translational research and accelerate high-quality drug development globally.Founded in 2010 and listed in 2021, ACROBiosystems Group is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and healthcare industries by providing innovative products and business models.
More news about: ACROBiosystems Group
May 08, 2026, 08:20 ET INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
[email protected] ALLEGATIONS: ImmunityBio is a biotechnology company that focuses on innovating, developing, and commercializing next-generation immunotherapies. According to the complaint, ImmunityBio's
More news about: Robbins Geller Rudman & Dowd LLP
May 08, 2026, 08:05 ET INOVIO to Participate in Upcoming Scientific Conferences
PLYMOUTH MEETING, Pa., May 8, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious
More news about: INOVIO Pharmaceuticals, Inc.
May 08, 2026, 07:30 ET Soligenix Announces Recent Updates and First Quarter 2026 Financial Results
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
May 08, 2026, 06:21 ET TOOTOO Self-Develops Ultra-Olaflur, Achieving a New Breakthrough in Super Cavity Protection for Children's Toothpaste
May 8, 2026 /PRNewswire/ -- Recently, Chinese children's age-specific wash and care brand TOOTOO (a brand under Hangzhou Daoyu Xingqing Biotechnology Co., Ltd.) has achieved a major scientific research breakthrough in the field of children's oral care. The company's three-year self-developed Ultra-Olaflur
More news about: TOOTOO
May 08, 2026, 05:56 ET BioQ Debuts at in‑cosmetics Global, Showcasing China's Advancing Strength in Ingredient Innovation
PARIS, May 8, 2026 /PRNewswire/ -- BioQ, the biotechnology affiliate of Chinese skincare brand GUYU, made its first appearance as a raw-material supplier at in-cosmetics Global, held April 14–16, 2026, in Paris. Widely regarded
More news about: BioQ
May 08, 2026, 05:34 ET BioQ Debuts at in‑cosmetics Global, Showcasing China's Advancing Strength in Ingredient Innovation
PARIS, May 8, 2026 /PRNewswire/ -- BioQ, the biotechnology affiliate of Chinese skincare brand GUYU, made its first appearance as a raw-material supplier at in-cosmetics Global, held April 14–16, 2026, in Paris. Widely regarded
More news about: BioQ
May 08, 2026, 02:30 ET Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
LinkedIn.About Biogen Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient's lives and to create value for shareholders and our communities.
More news about: Eisai Co., Ltd.